The 2022 Tandem Meetings | Safety and efficacy of new TKIs in Ph+ ALL
Usman Ali Akbar
• 19 Apr 2022
Usman Ali Akbar, MBBS, University of Louisville, Louisville, KY, comments on the efficacy and toxicity profile of new tyrosine kinase inhibitors (TKIs) as compared to older TKIs and chemotherapy in the treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Newer TKIs are more efficacious and are associated with fewer side effects than older TKIs and chemotherapy. Nevertheless, randomized clinical trials are required to incorporate these drugs in the treatment algorithm of Ph+ ALL. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
